Peking University Cancer Hospital & Institute

This phase II trial is testing whether the immunotherapy drug tislelizumab can help control locally advanced non-small cell lung cancer when given after radiation therapy or sequential chemoradiation. The study enrolls people with stage III lung cancer who cannot tolerate the sta…

This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the t…

This trial is for women with advanced breast cancer that has both hormone receptors (HR-positive) and the HER2 protein (HER2-positive). It tests whether adding a CDK4/6 inhibitor called palbociclib to standard endocrine therapy and anti-HER2 antibodies (trastuzumab and pertuzumab…